Skip to content
March 28, 2024

Equity.Guru

Investment information for the new generation

Search

EB613

Entera Bio (ENTX.Q) has announced the final 6-month bone mineral density (BMD) results from its Phase 2 clinical trial of EB613 for the treatment of osteoporosis. “We are very…